|
|
|
Volumn 23, Issue 1, 2004, Pages 34-35
|
|
Immunogenicity and safety of 10 mg and 20 mg doses of Genevac-B, a recombinant hepatitis B vaccine, in healthy adolescents [2]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BLOOD DERIVATIVE;
CORTICOSTEROID;
GENEVAC B;
GROWTH HORMONE;
HEPATITIS B CORE ANTIBODY;
HEPATITIS B SURFACE ANTIBODY;
HEPATITIS B SURFACE ANTIGEN;
IMMUNOGLOBULIN;
IMMUNOGLOBULIN M;
RECOMBINANT HEPATITIS B VACCINE;
ADOLESCENCE;
ADOLESCENT;
ADULT;
ALLERGY;
ANTIBODY TITER;
BLOOD CLOTTING DISORDER;
BLOOD SAMPLING;
CHILD;
CLINICAL EXAMINATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DELTOID MUSCLE;
DISEASE CARRIER;
DOSE RESPONSE;
DRUG SAFETY;
EDEMA;
FEVER;
FISHER EXACT TEST;
FOLLOW UP;
HEMATOLOGY;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATOMEGALY;
HUMAN;
IMMUNIZATION;
IMMUNOGENICITY;
IMMUNOSUPPRESSIVE TREATMENT;
INFORMED CONSENT;
INJECTION PAIN;
KIDNEY FUNCTION TEST;
LETTER;
LIVER FUNCTION TEST;
NONHUMAN;
NORMAL HUMAN;
RANDOMIZATION;
SEROCONVERSION;
SKIN DISEASE;
SPLENOMEGALY;
VACCINATION;
ADOLESCENT;
CHILD;
FEMALE;
HEPATITIS B VACCINES;
HUMANS;
MALE;
VACCINES, DNA;
|
|
EID: 1842712665
PISSN: 02548860
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (8)
|
|
References (4)
|
